

FIGURE 1. T and B cell development is normal in $Klf12$ -deficient mice. **(A)** Percentages and total cell numbers of $CD4^+$ and $CD8^+$ T cells in the thymus (*left panels*) and in the spleen (*right panels*). **(B)** Percentages and total cell numbers of developmental B cell subsets in the BM (*left panels*), spleen (*second left panels*), lymph node (*second right panels*), and peritoneal cavity (*right panels*). Subsets in the BM are defined as FrC' pro-B cells: $CD19^+IgM^-B220^+CD43^+CD24^+$; FrD pre-B cells: $CD19^+IgM^-B220^+CD43^-$; FrE immature B cells: $CD19^+IgM^+B220^+AA4.1^+CD24^{hi}$; and FrF mature B cells: $CD19^+IgM^+B220^+AA4.1^-CD24^+$. Subsets in the spleen are defined as T3 (transitional stage 3) B cells: $IgM^+IgD^+CD19^+B220^+AA4.1^+CD23^+$; FO (follicular) B cells: $IgM^+IgD^+CD19^+B220^+AA4.1^-CD23^+$; and MZ (marginal zone) B cells: $IgM^+IgD^+CD19^+B220^+AA4.1^-CD23^-$. Subsets in the lymph node are defined as FO (follicular) B cells: $IgM^+IgD^+CD19^+B220^+AA4.1^-CD23^+CD21^+CD43^-$. Subsets in the peritoneal cavity are defined as B2 follicular B cells: $IgM^+IgD^+CD19^+CD43^-CD23^+CD5^-$; B1a B cells: $IgM^+IgD^+CD19^+CD43^-B220^+CD5^+$; and B1b B cells: $IgM^+IgD^+CD19^+CD43^+B220^+CD5^-CD11b^+$. Data are representative of 4 experiments ($n = 3$ mice/genotype/experiment).




FIGURE 2. Upregulation of pERK is normal in *Klf12*-deficient T and B cells. **(A)** Representative histograms of pERK upregulation in lymph node CD4⁺, CD8⁺ T cells, and CD19⁺ B cells from *Klf12*^{+/+}, *Klf12*^{F/+}, and *Klf12*^{F/F} mice stimulated with anti-CD3 or anti-IgM. **(B)** Percentage and MFI of pERK in CD4⁺ T cells (*left panels*), CD8⁺ T cells (*middle panels*), and CD19⁺ T cells (*right panels*). Data are representative of 4 experiments ($n = 2-3$ mice/genotype/experiment).




FIGURE 3. T and B cell proliferation is normal in *Klf12*-deficient mice. Proliferation of *Klf12*^{+/+}, *Klf12*^{F/+}, and *Klf12*^{F/F} lymph node CD4⁺ T cells (*left panels*), CD8⁺ T cells (*middle panels*), and CD19⁺ T cells (*right panels*) after *in vitro* stimulation for 2-5 days with anti-CD3 and anti-IgM. Data are representative of 4 experiments ($n = 2-3$ mice/genotype/experiment).




FIGURE 4. Normal numbers of *Klf12*-deficient T cells from MCMV-infected BM chimeric mice. Relative numbers of naïve ($CD44^{lo}CD62L^{+}$) $CD4^{+}$ T cells, effector-memory ($CD44^{hi}CD62L^{-}$) $CD4^{+}$ T cells, naïve ($CD44^{-}CD62L^{+}$) $CD8^{+}$ T cells, effector-memory ($CD44^{+}CD62L^{lo/+}$) $CD8^{+}$ cells, and MCMV-specific $NKG2D^{+}CD8^{+}$ T cells in the blood following MCMV infection. Data are representative of 4 experiments ($n = 3-6$ mice/experiment).